ECSP109886A - Compuestos heterocíclicos de amidas como inhibidores de la proteincinasa - Google Patents

Compuestos heterocíclicos de amidas como inhibidores de la proteincinasa

Info

Publication number
ECSP109886A
ECSP109886A EC2010009886A ECSP109886A ECSP109886A EC SP109886 A ECSP109886 A EC SP109886A EC 2010009886 A EC2010009886 A EC 2010009886A EC SP109886 A ECSP109886 A EC SP109886A EC SP109886 A ECSP109886 A EC SP109886A
Authority
EC
Ecuador
Prior art keywords
disease
compounds
proteincinase
hiderocyclic
amidas
Prior art date
Application number
EC2010009886A
Other languages
English (en)
Inventor
Timothy J Guzi
M Arshad Siddiqui
Lianyun Zhao
Panduranga A Reddy
Praveen K Tadikonda
Tzu Tshin Wong
Shuyi Tang
Luis E Torres
David F Cauble
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP109886A publication Critical patent/ECSP109886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

El presente invento se relaciona con compuestos noveles de amida heterocíclica de la Fórmula I: Fórmula Isegún se da a conocer en el presente o una sal, solvato, éster, prodroga o estereoisómero de ésta. También se dan a conocer composiciones que comprenden dichos compuestos y métodos para su utilización para el tratamiento o la prevención de una enfermedad proliferativa, un desorden antiproliferativo, inflamación, artritis, una enfermedad neurológica o neurodegenerativa, una enfermedad cardiovascular, alopecia, una enfermedad neuronal, una lesión isquémica, una enfermedad virósica o fúngica.
EC2010009886A 2007-07-19 2010-01-19 Compuestos heterocíclicos de amidas como inhibidores de la proteincinasa ECSP109886A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95070907P 2007-07-19 2007-07-19

Publications (1)

Publication Number Publication Date
ECSP109886A true ECSP109886A (es) 2010-02-26

Family

ID=40070807

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009886A ECSP109886A (es) 2007-07-19 2010-01-19 Compuestos heterocíclicos de amidas como inhibidores de la proteincinasa

Country Status (20)

Country Link
US (1) US8293747B2 (es)
EP (1) EP2178861B1 (es)
JP (1) JP5241834B2 (es)
KR (1) KR101552742B1 (es)
CN (1) CN101801958B (es)
AR (1) AR067585A1 (es)
AU (1) AU2008279776B2 (es)
BR (1) BRPI0814441A2 (es)
CA (1) CA2693967A1 (es)
CL (1) CL2008002131A1 (es)
CO (1) CO6290765A2 (es)
EC (1) ECSP109886A (es)
IL (1) IL203354A (es)
MY (1) MY150032A (es)
NZ (1) NZ582708A (es)
PE (1) PE20090905A1 (es)
RU (1) RU2474580C2 (es)
TW (1) TWI371275B (es)
WO (1) WO2009014637A2 (es)
ZA (1) ZA201000366B (es)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501406C2 (sv) 1993-06-07 1995-02-06 Iggesund Shredders Ab Anordning innefattande ett ramverk och ett i detta roterbart lagrat element
EP2535330A3 (en) * 2006-10-23 2012-12-26 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
AR071392A1 (es) * 2008-04-23 2010-06-16 Takeda Pharmaceutical Derivados de iminopiridina y su uso
AU2013206248B2 (en) * 2008-06-27 2016-06-23 Xenon Pharmaceuticals Inc. Organic compounds
AU2011265439B2 (en) * 2008-09-02 2012-09-20 Novartis Ag Picolinamide derivatives as kinase inhibitors
PL2344474T3 (pl) * 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010080503A1 (en) * 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CA2759083A1 (en) 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
AU2011209051B2 (en) * 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
JP6161537B2 (ja) * 2010-04-07 2017-07-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011149874A2 (en) * 2010-05-26 2011-12-01 Schering Corporation N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
US20130109682A1 (en) * 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
CN102924446B (zh) * 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
WO2013039854A1 (en) * 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
EP2891656A4 (en) 2012-08-30 2016-03-02 Nippon Shinyaku Co Ltd PYRIDINE DERIVATIVE AND MEDICAMENT THEREFOR
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
AR096151A1 (es) 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
AU2014345594B2 (en) * 2013-11-05 2018-11-08 Elanco Animal Health Gmbh Substituted benzamides for the treatment of arthropods
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
US10730866B2 (en) * 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016024350A1 (ja) 2014-08-13 2016-02-18 株式会社エス・ディー・エス バイオテック 縮合１１員環化合物及びそれらを含有する農園芸用殺菌剤
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
JP6407457B2 (ja) 2016-02-08 2018-10-17 株式会社エス・ディー・エス バイオテック １，２−ベンゼンジメタノール化合物の製造方法
WO2017138069A1 (ja) 2016-02-08 2017-08-17 株式会社エス・ディー・エス バイオテック 殺菌性組成物
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
AU2017246547B2 (en) 2016-04-04 2023-02-23 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
ES2878078T3 (es) * 2016-11-28 2021-11-18 Bristol Myers Squibb Co Inhibidores de GSK-3
KR102455408B1 (ko) * 2016-11-28 2022-10-14 브리스톨-마이어스 스큅 컴퍼니 Gsk-3 억제제로서의 피리미딘 카르복스아미드
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019079369A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
CN107641095A (zh) * 2017-11-16 2018-01-30 常州合全药业有限公司 一种7‑甲氧基异吲哚‑1‑酮的合成方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3755703B1 (en) * 2018-02-20 2022-05-04 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
AR116024A1 (es) * 2018-08-29 2021-03-25 Seal Rock Therapeutics Inc Métodos de tratamiento de enfermedades neurodegenerativas
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
BR112022002059A2 (pt) 2019-08-06 2022-06-07 Incyte Corp Formas sólidas de um inibidor de hpk1
US20230101747A1 (en) 2019-12-06 2023-03-30 Schrödinger, Inc. Cyclic compounds and methods of using same
IL294214B2 (en) 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
CN111592533B (zh) * 2020-06-16 2021-08-24 浙江工业大学 1,2,4-噁二唑联吡啶取代苯甲酰胺类化合物及其制备方法和应用
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CA3195121A1 (en) 2020-10-09 2022-04-14 Robert A. Volkmann Heteroaryl amide inhibitors of cd38
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
AU2022256514A1 (en) * 2021-04-16 2023-10-19 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating cancer
WO2023030478A1 (zh) * 2021-09-03 2023-03-09 浙江海正药业股份有限公司 吡啶并内酰胺类衍生物及其制备方法和用途
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023250399A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2024137984A1 (en) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
CN116199636A (zh) * 2023-02-21 2023-06-02 杭州医学院 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用
WO2025059027A1 (en) 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
AU2001231143A1 (en) * 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
TW200424174A (en) * 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
WO2005005429A1 (en) * 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2006053227A2 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
CA2679659C (en) * 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.

Also Published As

Publication number Publication date
US20100286135A1 (en) 2010-11-11
JP5241834B2 (ja) 2013-07-17
CA2693967A1 (en) 2009-01-29
RU2010105678A (ru) 2011-08-27
EP2178861B1 (en) 2014-08-20
KR101552742B1 (ko) 2015-09-11
CN101801958A (zh) 2010-08-11
AR067585A1 (es) 2009-10-14
IL203354A (en) 2013-12-31
TW200920370A (en) 2009-05-16
MY150032A (en) 2013-11-29
RU2474580C2 (ru) 2013-02-10
PE20090905A1 (es) 2009-07-13
ZA201000366B (en) 2010-10-27
WO2009014637A2 (en) 2009-01-29
WO2009014637A3 (en) 2009-03-19
JP2010533716A (ja) 2010-10-28
EP2178861A2 (en) 2010-04-28
CL2008002131A1 (es) 2009-01-23
TWI371275B (en) 2012-09-01
CO6290765A2 (es) 2011-06-20
BRPI0814441A2 (pt) 2015-07-14
CN101801958B (zh) 2014-01-29
AU2008279776B2 (en) 2013-05-23
AU2008279776A2 (en) 2010-02-18
NZ582708A (en) 2012-04-27
US8293747B2 (en) 2012-10-23
KR20100045481A (ko) 2010-05-03
AU2008279776A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
ECSP109886A (es) Compuestos heterocíclicos de amidas como inhibidores de la proteincinasa
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
WO2009143039A3 (en) Heterocyclic compounds as factor ixa inhibitors
CR20140413A (es) Inhibidores de serina/treonina cinasa
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
NI201200059A (es) PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
GT201200038A (es) Composicion para tratar la fibrosis quistica
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
BRPI0610322B8 (pt) inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2016002548A1 (es) Derivados de tubulisina
CR20110103A (es) Heteroarilos sustituidos
BR112013023847A2 (pt) composições farmacêuticas compreendendo ésteres de sorbitano
CY1124419T1 (el) Συνθεσεις προφαρμακων φουμαρικου μονομεθυλεστερα
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201200193A (es) Derivados de aril triazol heteroarmoaticos como inhibidores de enzima pde10a
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
BR112013023266A8 (pt) Inibidores da girase tricíclicos
MX345287B (es) Nuevas composiciones para tratar cmt y trastornos relacionados.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201001524A1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате